DE60043126D1 - Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten - Google Patents

Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten

Info

Publication number
DE60043126D1
DE60043126D1 DE60043126T DE60043126T DE60043126D1 DE 60043126 D1 DE60043126 D1 DE 60043126D1 DE 60043126 T DE60043126 T DE 60043126T DE 60043126 T DE60043126 T DE 60043126T DE 60043126 D1 DE60043126 D1 DE 60043126D1
Authority
DE
Germany
Prior art keywords
adenovirus
type
serotypes
tropism
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60043126T
Other languages
English (en)
Inventor
Menzo Jans Emco Havenga
Abraham Bout
Ronald Vogels
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Original Assignee
Crucell Holand BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240209&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60043126(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crucell Holand BV filed Critical Crucell Holand BV
Application granted granted Critical
Publication of DE60043126D1 publication Critical patent/DE60043126D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60043126T 1999-05-17 2000-05-16 Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten Expired - Lifetime DE60043126D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99201545 1999-05-17

Publications (1)

Publication Number Publication Date
DE60043126D1 true DE60043126D1 (de) 2009-11-19

Family

ID=8240209

Family Applications (4)

Application Number Title Priority Date Filing Date
DE60045138T Expired - Lifetime DE60045138D1 (de) 1999-05-17 2000-05-16 Rekombinantes Adenovirus des Ad26-Serotyps
DE60014489T Expired - Lifetime DE60014489T3 (de) 1999-05-17 2000-05-16 Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten
DE60043126T Expired - Lifetime DE60043126D1 (de) 1999-05-17 2000-05-16 Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten
DE60035229T Expired - Lifetime DE60035229T2 (de) 1999-05-17 2000-05-16 Rekombinanter humaner Adenovirus-Serotyp 35

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE60045138T Expired - Lifetime DE60045138D1 (de) 1999-05-17 2000-05-16 Rekombinantes Adenovirus des Ad26-Serotyps
DE60014489T Expired - Lifetime DE60014489T3 (de) 1999-05-17 2000-05-16 Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60035229T Expired - Lifetime DE60035229T2 (de) 1999-05-17 2000-05-16 Rekombinanter humaner Adenovirus-Serotyp 35

Country Status (14)

Country Link
EP (6) EP1818408B1 (de)
JP (2) JP4843145B2 (de)
KR (1) KR100741247B1 (de)
AT (6) ATE519854T1 (de)
AU (1) AU777041B2 (de)
CA (1) CA2372655C (de)
CY (4) CY1106762T1 (de)
DE (4) DE60045138D1 (de)
DK (6) DK1816204T3 (de)
ES (5) ES2372824T3 (de)
IL (3) IL146479A0 (de)
NZ (1) NZ515582A (de)
PT (5) PT1816205E (de)
WO (1) WO2000070071A1 (de)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122614A0 (en) 1995-06-15 1998-08-16 Introgene Bv Packaging systems for human recombinant adenovirus to be used in gene therapy
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US7094398B1 (en) 1999-06-01 2006-08-22 University Of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
US6558948B1 (en) 1999-11-23 2003-05-06 Stefan Kochanek Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
EP1191105A1 (de) * 2000-09-25 2002-03-27 Galapagos Genomics B.V. Gentransfervektoren mit einer Gewebsspezifität für T-Lymphozyten
WO2001092547A2 (en) 2000-05-31 2001-12-06 University Of Saskatchewan Modified bovine adenovirus having altered tropism
WO2002024730A2 (en) * 2000-09-20 2002-03-28 Crucell Holland B.V. Transduction of dendritic cells using adenoviral vectors
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
EP1195440A1 (de) * 2000-10-06 2002-04-10 Introgene B.V. Genverabreichung-Vektoren für Stammzellen
WO2002029073A2 (en) * 2000-10-06 2002-04-11 Crucell Holland B.V. Gene delivery vectors for stem cells
DE60234496D1 (de) 2001-01-04 2010-01-07 Goeran Wadell Virusvektor zur gentherapie
JP2004536572A (ja) 2001-02-23 2004-12-09 セル・ジェネシス・インコーポレイテッド 新規ベクター構築物
JP4488290B2 (ja) * 2002-01-24 2010-06-23 ザ・スクリップス・リサーチ・インスティテュート 効率的ターゲティングのためのファイバーシャフト変異
ES2335657T3 (es) * 2002-04-25 2010-03-31 Crucell Holland B.V. Medios y metodos para la produccion de vectores de adenovirus.
ATE405663T1 (de) * 2002-04-25 2008-09-15 Crucell Holland Bv Stabile adenovirale vektoren und methoden für deren vermehrung
JP4237449B2 (ja) * 2002-06-05 2009-03-11 国立医薬品食品衛生研究所長 アデノウィルスベクター
EP1553983A2 (de) 2002-10-23 2005-07-20 Crucell Holland B.V. Einstellung für rekombinante adenovirus-basierte impfstoffe
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
WO2004055187A1 (en) * 2002-12-17 2004-07-01 Crucell Holland B.V. Recombinant viral-based malaria vaccines
EP1646717A4 (de) * 2003-07-18 2006-12-20 Onyx Pharma Inc Adenovirus-untergruppe-b-vektoren zur behandlung von krankheiten
ES2329607T3 (es) 2004-02-23 2009-11-27 Crucell Holland B.V. Metodos de purificacion de virus.
CA2563396A1 (en) * 2004-04-12 2005-11-24 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Method of using adenoviral vectors to induce an immune response
KR101169109B1 (ko) 2004-05-26 2012-07-26 싸이오서스 테라퓨틱스 엘티디. 암 치료에 사용하기 위한 키메릭 아데노바이러스
NZ553889A (en) 2004-10-13 2009-11-27 Crucell Holland Bv Replication-defective adenovirus comprising a chimeric hexon protein and replaced hypervariable ragions HVR1-7
KR101255870B1 (ko) 2004-11-16 2013-04-17 아에라스 글로벌 티비 백신 파운데이션 재조합 바이러스 벡터를 포함하는 다가 백신
ATE412737T1 (de) 2005-04-11 2008-11-15 Crucell Holland Bv Virusreinigung mit ultrafiltration
CA2616221C (en) 2005-07-22 2011-07-05 Crucell Holland B.V. Cell line for producing coronaviruses
US20100143302A1 (en) * 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
PL2350268T3 (pl) 2008-11-03 2015-05-29 Crucell Holland Bv Sposób wytwarzania wektorów adenowirusowych
KR20120052352A (ko) 2009-08-07 2012-05-23 트랜스진 에스.에이. Ｈｂｖ 감염을 치료하는 조성물
NZ601424A (en) 2010-02-15 2014-07-25 Crucell Holland Bv Method for the production of ad26 adenoviral vectors
US20120315696A1 (en) * 2010-02-15 2012-12-13 Alfred Luitjens METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS
CA2808556A1 (en) 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
MX354752B (es) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
CN102260712B (zh) * 2011-05-31 2013-10-02 北京锤特生物科技有限公司 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
SG11201405228VA (en) 2012-03-12 2014-11-27 Crucell Holland Bv Batches of recombinant adenovirus with altered terminal ends
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
EP2827895B1 (de) 2012-03-22 2017-08-09 Janssen Vaccines & Prevention B.V. Impfstoff gegen rsv
JP6162224B2 (ja) 2012-05-24 2017-07-12 クルセル ホランド ベー ヴェー 血管組織の形質導入のためのアデノウイルスベクター
TWI638829B (zh) 2012-07-10 2018-10-21 法商傳斯堅公司 分枝桿菌抗原疫苗
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
SG11201503864TA (en) 2012-11-16 2015-06-29 Beth Israel Hospital Recombinant adenoviruses and use thereof
WO2014153204A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
AP2015008815A0 (en) 2013-04-25 2015-10-31 Crucell Holland Bv Stabilized soluble prefusion rsv f polypeptides
MY171210A (en) 2013-06-17 2019-10-02 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f polypeptides
SG11201602887QA (en) 2013-10-25 2016-05-30 Psioxus Therapeutics Ltd Oncolytic adenoviruses armed with heterologous genes
US10765731B2 (en) 2014-01-09 2020-09-08 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
BR112017004202A2 (pt) 2014-09-03 2019-09-03 Bavarian Nordic As composições para intensificar respostas imunes e seus usos
BR112017003891A2 (pt) 2014-09-03 2017-12-26 Bavarian Nordic As métodos e composições para induzir imunidade protetora contra infecção por filovírus
EA037583B1 (ru) 2014-09-26 2021-04-16 Бет Изрейэл Диконисс Медикал Сентер, Инк. Способы и композиции для индукции защитного иммунитета против инфекции вирусом иммунодефицита человека
MY181175A (en) 2014-11-04 2020-12-21 Janssen Vaccines & Prevention Bv Therapeutic hpv16 vaccines
SI3283634T1 (sl) 2015-04-14 2019-08-30 Janssen Vaccines & Prevention B.V. Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem
AU2016256582B2 (en) 2015-04-30 2020-10-29 Akamis Bio Limited Oncolytic adenovirus encoding a B7 protein
EP3319634B1 (de) 2015-07-07 2019-08-21 Janssen Vaccines & Prevention B.V. Stabilisierte lösliche präfusionierte rsv-f-polypeptide
JP7189014B2 (ja) 2015-07-07 2022-12-13 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
EA037295B1 (ru) 2015-08-20 2021-03-05 Янссен Вэксинс Энд Превеншн Б.В. Терапевтические вакцины против hpv18
PT3390430T (pt) 2015-12-15 2019-11-20 Janssen Vaccines & Prevention Bv Antígenos, vetores, composições para o vírus da imunodeficiência humana e métodos da sua utilização
EA201891021A1 (ru) 2015-12-17 2018-11-30 Псайоксус Терапьютикс Лимитед Аденовирус группы b, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
KR20180112024A (ko) 2016-02-23 2018-10-11 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
DK3439672T3 (da) 2016-04-05 2021-02-15 Janssen Vaccines & Prevention Bv Stabiliserede opløselige præfusions-rsv-f-proteiner
JP7233928B2 (ja) 2016-04-05 2023-03-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
CN109922829A (zh) 2016-05-02 2019-06-21 扬森疫苗与预防公司 治疗性hpv疫苗组合
ES2836598T3 (es) 2016-05-30 2021-06-25 Janssen Vaccines & Prevention Bv Proteínas F de RSV prefusión estabilizadas
KR102389489B1 (ko) 2016-06-16 2022-04-22 얀센 백신스 앤드 프리벤션 비.브이. Hiv 백신 제형
CN109312362B (zh) 2016-06-20 2022-06-28 扬森疫苗与预防公司 有效和平衡的双向启动子
JP7229151B2 (ja) 2016-07-14 2023-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｐｖワクチン
EP3484505A1 (de) 2016-07-15 2019-05-22 Janssen Vaccines & Prevention B.V. Verfahren und zusammensetzungen zur induzierung von schützender immunität gegen marburg-virus-infektionen
US10925956B2 (en) 2016-07-15 2021-02-23 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
EP4273252A3 (de) 2016-08-29 2024-04-17 Akamis Bio Limited Adenovirus mit bispezifischem t-zell-engager (bite)
CN110062630A (zh) 2016-12-12 2019-07-26 萨克生物研究学院 肿瘤靶向合成腺病毒及其用途
AU2018217935B2 (en) 2017-02-09 2020-04-30 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
WO2018185732A1 (en) 2017-04-06 2018-10-11 Janssen Vaccines & Prevention B.V. Mva-bn and ad26.zebov or ad26.filo prime-boost regimen
JP2020519663A (ja) 2017-05-17 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
EP3638302B1 (de) 2017-06-15 2024-03-13 Janssen Vaccines & Prevention B.V. Hiv-antigene codierende pockenvirusvektoren und verfahren zu deren verwendung
SG11202001458SA (en) 2017-09-15 2020-03-30 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv
US10864263B2 (en) 2017-11-20 2020-12-15 Janssen Pharmaceuticals, Inc. Method of providing safe administration of adenoviral vectors encoding a zika virus antigen
EP3723771A4 (de) 2017-12-11 2022-04-06 Beth Israel Deaconess Medical Center, Inc. Rekombinante adenoviren und verwendungen davon
MX2020006471A (es) 2017-12-19 2020-09-22 Janssen Sciences Ireland Unlimited Co Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv).
US11713469B2 (en) 2018-07-20 2023-08-01 Janssen Vaccines & Prevention B.V. Recombinant adenoviral vector expressing Zika antigen with improved productivity
BR112021013507A2 (pt) 2019-01-10 2021-11-16 Janssen Biotech Inc Neoantígenos da próstata e seus usos
AU2020275455A1 (en) 2019-05-15 2021-12-09 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
CN113950333A (zh) 2019-05-15 2022-01-18 扬森疫苗与预防公司 使用基于腺病毒的疫苗预防性治疗呼吸道合胞病毒感染
BR112022009598A2 (pt) 2019-11-18 2022-08-16 Janssen Biotech Inc Vacinas baseadas em calr e jak2 mutantes e uso dos mesmos
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
CN111337042B (zh) * 2020-03-13 2021-11-02 湖北大学 一种车辆路径规划方法及系统
WO2021209897A1 (en) 2020-04-13 2021-10-21 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
US20230035403A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Method For Determining Responsiveness To Prostate Cancer Treatment
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
US20230029453A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
BR112022027038A2 (pt) 2020-07-08 2023-01-24 Janssen Sciences Ireland Unlimited Co Vacinas de replicon de rna contra hbv
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
US20230374542A1 (en) 2020-10-07 2023-11-23 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21)
WO2022140759A2 (en) 2020-12-23 2022-06-30 Janssen Biotech, Inc. Neoantigen peptide mimics
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2725726B1 (fr) * 1994-10-17 1997-01-03 Centre Nat Rech Scient Vecteurs viraux et utilisation en therapie genique
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
IL122614A0 (en) 1995-06-15 1998-08-16 Introgene Bv Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5877011A (en) * 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
US6100086A (en) * 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
EP1159438B1 (de) * 1999-03-04 2008-07-30 Crucell Holland B.V. Verwendung eines adenovirusvektors zur transduktion von synovialen zellen
US20110129498A1 (en) * 2008-06-03 2011-06-02 Okairos Ag Vaccine for the prevention and therapy of hcv infections

Also Published As

Publication number Publication date
ATE485382T1 (de) 2010-11-15
DK1818408T3 (da) 2011-10-17
IL146479A (en) 2011-12-29
JP4843145B2 (ja) 2011-12-21
ES2231103T3 (es) 2005-05-16
PT1818408E (pt) 2011-11-15
DE60035229D1 (de) 2007-07-26
EP1550722A1 (de) 2005-07-06
ATE278792T1 (de) 2004-10-15
IL214413A0 (en) 2011-09-27
ATE445018T1 (de) 2009-10-15
CA2372655C (en) 2011-11-15
DE60014489T3 (de) 2010-08-12
DE60035229T2 (de) 2008-02-21
CY1112189T1 (el) 2015-12-09
AU777041B2 (en) 2004-09-30
DE60045138D1 (de) 2010-12-02
EP1054064B2 (de) 2009-12-16
PT1816205E (pt) 2011-11-15
JP2002543846A (ja) 2002-12-24
CY1112008T1 (el) 2015-11-04
DK1681353T3 (da) 2010-01-04
ATE364707T1 (de) 2007-07-15
JP2011224014A (ja) 2011-11-10
PT1550722E (pt) 2007-09-25
ES2354578T3 (es) 2011-03-16
EP1818408B1 (de) 2011-08-10
EP1681353A1 (de) 2006-07-19
EP1816204B1 (de) 2010-10-20
IL146479A0 (en) 2002-07-25
DK1550722T3 (da) 2007-10-08
EP1550722B1 (de) 2007-06-13
KR100741247B1 (ko) 2007-07-19
EP1681353B1 (de) 2009-10-07
WO2000070071A1 (en) 2000-11-23
DE60014489T2 (de) 2005-11-24
CY1106762T1 (el) 2012-05-23
ATE519854T1 (de) 2011-08-15
DK1816204T3 (da) 2011-01-24
DK1054064T4 (da) 2010-05-03
PT1054064E (pt) 2005-02-28
JP5335037B2 (ja) 2013-11-06
EP1054064B1 (de) 2004-10-06
EP1818408A1 (de) 2007-08-15
KR20020028879A (ko) 2002-04-17
EP1816204A1 (de) 2007-08-08
EP1816205B1 (de) 2011-08-10
PT1816204E (pt) 2011-01-24
EP1054064A1 (de) 2000-11-22
ES2289426T3 (es) 2008-02-01
ATE519855T1 (de) 2011-08-15
NZ515582A (en) 2003-11-28
AU4954700A (en) 2000-12-05
IL214413A (en) 2014-04-30
ES2372823T3 (es) 2012-01-26
ES2231103T5 (es) 2010-04-15
ES2372824T3 (es) 2012-01-26
EP1816205A1 (de) 2007-08-08
DK1054064T3 (da) 2005-01-10
DE60014489D1 (de) 2004-11-11
CY1111494T1 (el) 2015-08-05
CA2372655A1 (en) 2000-11-23
DK1816205T3 (da) 2011-11-21

Similar Documents

Publication Publication Date Title
DE60014489D1 (de) Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten
ATE278789T1 (de) Hilfsfunktionen fuer die rekombinante aav- virionherstellung
FI951138A (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
EP1015005A4 (de) Gentransfer mit hilfe von adenovirus enthaltend modifizierte faserproteine
AU5464000A (en) Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins
WO2002018948A3 (en) Differentially expressed epitopes and uses thereof
WO2003099859A3 (de) Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
EP1270586A3 (de) Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen
AU2002228805A1 (en) Antisense modulation of damage-specific dna binding protein 2, p48 expression
ATE293160T1 (de) Nicht-embryonale ependymale neuronale stammzellen und methoden zu ihrer isolierung
WO2006086357A3 (en) Adenovirus serotype 36 vectors, nucleic acid and viruses produced thereby
WO2002083896A3 (en) Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same
ATE428793T1 (de) Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
WO2001077293A3 (en) Gp40 and uses thereof
Chin Rescuing Glycine
Powers Raising Caen.
Asgharian et al. A comparative monomolecular film study of 1, 2-di-O-palmitoyl-3-O-(. alpha.-and. beta.-D-glucopyranosyl)-sn-glycerols [Erratum to document cited in CA111 (11): 92542q]
Nishida From Cell Motility to Cell Biology
坂口実 TWO-PERSON HI-LO POKER: STUD AND DRAW, II
Heldin Different Dimeric Forms of PDGF have Different Functional Activities
Banks The upper airway.
Kacich et al. The papers are brief and well illustrated. The section on megacolon, an unusual adult abnormality, is particularly well done. This is a report of a meeting and not an authoritative, complete monograph on surgery of the colon and rectum. The cost in paperback is $30, and would be

Legal Events

Date Code Title Description
8364 No opposition during term of opposition